Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company Deals

Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products

Fineline Cube Sep 19, 2023

UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic...

Company Deals

Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development

Fineline Cube Sep 18, 2023

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm...

Company Drug

EMA’s CHMP Backs Enhertu for Advanced NSCLC with HER2 Mutations

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

BMS Expands Partnership with Samsung Biologics for Oncology Drug Manufacturing

Fineline Cube Sep 18, 2023

Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing...

Company Drug

EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Novartis’s Kisqali Reduces Cancer Recurrence Risk in HR+/HER2- Early Breast Cancer: Phase III Results

Fineline Cube Sep 18, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has published results from a Phase III study of...

Company

CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases

Fineline Cube Sep 18, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...

Company Deals R&D

GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models

Fineline Cube Sep 18, 2023

Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in...

Company Drug

Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors

Fineline Cube Sep 18, 2023

Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...

Company Medical Device

AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy

Fineline Cube Sep 18, 2023

Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the...

Company Deals Digital

Baidu Health Partners with HOB Biotech to Innovate Allergy Detection and Treatment

Fineline Cube Sep 18, 2023

Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in...

Company Medical Device

Tuodao Medical’s Percutaneous Puncture Surgery Robot NP100 Approved in China

Fineline Cube Sep 18, 2023

China-based surgical robot developer Tuodao Medical Technology Co., Ltd has received marketing approval for its...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Irinotecan Liposome Injection

Fineline Cube Sep 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received market approval...

Company Medical Device

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

Fineline Cube Sep 18, 2023

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

Legal / IP

Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone

Fineline Cube Sep 18, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving...

Company

Astellas Pharma Invests EUR 330 Million in State-of-the-Art Manufacturing Plant in Ireland

Fineline Cube Sep 15, 2023

Japanese pharmaceutical company Astellas Pharma (TYO: 4503) has announced a significant investment of EUR 330...

Company Policy / Regulatory

China Launches Fourth National Volume-Based Procurement Tender Focusing on Medical Consumables

Fineline Cube Sep 15, 2023

The national high-value medical consumables joint procurement office has released a notification, marking the commencement...

Company

J&J Rebrands Pharmaceutical and MedTech Segments Post-Kenvue Separation

Fineline Cube Sep 15, 2023

Following the completion of its consumer healthcare unit separation as Kenvue (NYSE: KVUE) last month,...

Company Drug

Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment

Fineline Cube Sep 15, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has accepted for review a...

Company Drug

AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC

Fineline Cube Sep 15, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...

Posts pagination

1 … 434 435 436 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.